Press

 

Media presence is a key part of making society aware of developments in biotechnology and its benefits.This is where we post all our press releases. If you are a journalist interested in learning more about the biotechnology sector, contact Agathe Cortes, our Head of Communicationacortes@asebio.com

Search engine
Laboratorio_biotecnología_AseBio
Science and Innovation, the Pending Subject of Spain and a Weak Point in the Progress towards Strategic Autonomy
Healthcare · Access to innovation · Climate change · Agrifood · Industrial biotechnology · Financing · Talento
  • Beyond the direct impact of biotechnology on human health and the planet, investment in science and biotechnology has a direct relationship with the competitiveness, sustainability, and economic resilience of countries.
  • Biotechnological innovations will determine the well-being of future generations, but for this to happen and for Spain to fully harness its potential, there needs to be a political and social will that provides the industry with measures and resources to ensure its full development.
  • Spain needs a clear regulatory framework and support for the biotechnological industry with long-term investments, support that specifically addresses the needs of biotech companies, and measures to boost research talent.
AseBio
Edición_genética_AseBio
Genome editing techniques can help address the challenges facing agriculture and the planet
BioSpain
  • Ensuring food security and mitigating the impacts of climate change will not be possible without innovation in agriculture.
  • Through food waste and the insect industry, proteins are being produced in a more sustainable manner.
  • Biotechnology enables the transformation of certain types of waste into raw materials for industry, avoiding their disposal in landfills and reducing the footprint of processes and products.
AseBio
Clausura_BIOSPAIN_2023
BIOSPAIN 2023 concludes its eleventh edition with record-breaking participation figures
BioSpain
  • The President of the Generalitat de Catalunya, Pere Aragonès i Garcia, and the General Manager of Amgen and member of the Board of Directors of AseBio and the Board of Trustees of Biocat, Fina Lladós, officially close the fair.
  •  Over 2,100 attendees and more than 220 exhibitors gathered over the course of the three-day congress.
  • BIOSPAIN has evolved into a platform for fostering the next generation of startups, with over 5,000 one-to-one meetings and more than 30 startup presentations to investors.
AseBio
Resistencia_antibióticos_AseBio
The biotechnology industry has become a key player in the fight against antimicrobial resistance and the approach to rare diseases
BioSpain
  • The sector has radically transformed the discovery of new drugs and therapeutic solutions.
  • Worldwide, there are over 300 approved medications for approximately 250 indications and a thousand molecules in various stages of research.
  • Biotechnological development is opening new horizons in the field of mental health.
AseBio
Inversión_biotecnología_AseBio
External funding in the biotechnology sector will help achieve strategic autonomy for Spain and Europe
BioSpain
  • The majority of biotechnology companies are small and micro-enterprises that do not have products on the market and do not generate the necessary resources to finance their activities.
  • There is an increasing alignment between specialized venture capital and emerging biotechnology companies.
  • Strategic autonomy in the European healthcare sector can be supported in three areas: simplifying the European regulatory framework, reducing administrative burdens, and removing barriers to investment.
AseBio
BIOSPAIN
BIOSPAIN 2023: Biotechnology emerges as a response to the main challenges Europe is facing
BioSpain
  • The new edition of the international flagship event in the biotech sector will take place in Barcelona from September 26 to 28, in collaboration with Biocat, the Government of Catalonia, and the Barcelona City Council.
  • The BIOSPAIN 2023 program consists of more than 60 sessions that will analyze areas such as health, planetary sustainability, Europe's strategic autonomy, and global threats like antibiotic resistance, among other topics.
  • Within the framework of BIOSPAIN 2023, the "AseBio 2023 Journalism Awards" will be held. These awards highlight the excellent scientific journalism produced in Spain and will recognize journalists who give voice to the work of the Spanish biotechnology sector.
AseBio
Miembros_Consorcio_ShapingBio
ShapingBio will analyze the challenges and opportunities of the bioeconomy in Europe at BIOSPAIN 2023
BioSpain
  • The European project ShapingBio, created with the aim of better understanding and gaining knowledge of the innovation ecosystem in the European bioeconomy sector, will be present at BIOSPAIN.
  • Under the title "Shaping Bioeconomy in Europe," the session offered by ShapingBio at BIOSPAIN 2023 will delve into the challenges and opportunities that require special attention and consideration for promoting the bioeconomy in Europe.
AseBio
Biotecnología_AseBio
AseBio and EuropaBio address the challenges of the Pharmaceutical Strategy and NGTs in Europe
Healthcare · Agrifood
  • During the Presidency of the Council of the European Union, Spain will lead the dialogue on these critical policies for European patients, food safety, and the green transition.
  • "We need to find a path that ensures access for all patients to medications and reduces waiting times," says Ana Polanco, President of AseBio.
  • "Europe needs to define a predictable regulatory framework for new genome editing techniques. Only then can we harness our scientific, human, infrastructure, and raw material strengths to build a competitive ecosystem in industrial biotechnology," explains Ion Arocena, CEO of AseBio.
AseBio
Terapias_Avanzadas_AseBio
AseBio presents the ‘Map of advanced-therapy capacities of the biotech industry’ in Spain
Healthcare · Innovative drugs · Advanced therapies

Over 30 innovative biotech companies possess the comprehensive capabilities to develop advanced therapies, from initial R&D through manufacturing, efficient transfer and distribution

AseBio